-
European Journal of Cancer Prevention :... Mar 2021This study aimed to investigate whether the drug-specific and dosage effects of statin use were associated with a lower risk of cancer in adults in South Korea. We...
This study aimed to investigate whether the drug-specific and dosage effects of statin use were associated with a lower risk of cancer in adults in South Korea. We evaluated the adult population registered in the 2010 sample cohort database of South Korea. Subjects were divided into the statin group (those who had been prescribed continuous oral statin over 1 year) and the control group (those who had never been prescribed statin from 2010 to 2016). In total, 687 396 individuals were included in the analysis [statin group, 53 592 (7.8%); control group, 633 804 (92.2%)]. In a multivariable Cox model, the hazard of cancer in the statin group was 5% lower than that in the control group [hazard ratio, 0.95; 95% confidence interval (CI), 0.91-0.98; P = 0.004]. Additionally, the hazard of cancer in patients receiving moderate- and high-intensity daily dosages of statin were 5% (hazard ratio, 0.95; 95% CI, 0.91-0.98; P = 0.005) and 9% (hazard ratio, 0.91; 95% CI, 0.83-0.99; P = 0.042) lower than that of the control group, respectively. The hazard of cancer in patients receiving atorvastatin was 6% (hazard ratio, 0.94; 95% CI, 0.90-0.98; P = 0.005) lower than that in the control group, while other types of statins showed no significant associations (all P > 0.05). Statin use was associated with a lower risk of cancer in South Korea. This association was stronger in patients receiving moderate and high daily dosages of statin and in patients receiving atorvastatin.
Topics: Adult; Atorvastatin; Cohort Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Retrospective Studies
PubMed: 32483011
DOI: 10.1097/CEJ.0000000000000600 -
Journal of Hazardous Materials Mar 2021Coagulation has been accepted as a cost-effective and environmental-friendly method to remove pollutants. In our recent work, two coagulants of polyaluminum chloride...
Coagulation has been accepted as a cost-effective and environmental-friendly method to remove pollutants. In our recent work, two coagulants of polyaluminum chloride (PAC) and polyaluminum ferric chloride (PAFC) with dosage gradients, and one coagulant aid of anionic polyacrylamide (PAM) were used to investigate their potential to remove particle-associated (PA) and free-living (FL) ARGs and MGEs detected by high throughput qPCR (HT-qPCR) method. The results indicated that the maximum removal efficiencies of PA- and FL-ARGs (4.67- and 3.18-logs) were obtained at the PAFC dosage of 50.0 mg/L. Excessive PAFC dosage can hamper the removal of size-fractionated ARGs. As PAC aid, anionic PAM (1.0 mg/L) had limited effects to promote the removal of PA-ARG, while FL-ARG removal was enhanced by 0.34 log at the PAC dosage of 50.0 mg/L. The fitted curves suggested that the optimal chemical dosages of PAC, PAFC and PAC coupled with PAM in the removal of total ARGs and MGEs were 40.5, 64.7 and 50.0 mg/L, respectively. In addition, we found that much more coagulants were needed to remove FL-ARGs compared to that of PA-ARGs. The removal efficiencies of size-fractionated ARGs by flocculation can be affected by coagulant type, dosage, coagulant aid, Zeta potential and microorganism lifestyle (PA or FL).
Topics: Anti-Bacterial Agents; Flocculation; Wastewater
PubMed: 33153783
DOI: 10.1016/j.jhazmat.2020.124295 -
The Science of the Total Environment Jan 2023Mercapto-modified palygorskite (MP) is an efficient novel amendment with superior ability to decrease soil Cd bioavailability, but the unclear immobilization mechanism...
Mercapto-modified palygorskite (MP) is an efficient novel amendment with superior ability to decrease soil Cd bioavailability, but the unclear immobilization mechanism has become the bottleneck of its performance improvement and precise application. In order to clarify the Cd reducing mechanism of MP, long-term and short-term soil incubation with three types of soils (paddy soil, alluvial soil and yellow mountain soil) and sorption verification experiments were conducted to investigate the dynamic process of soil labile Cd impacted by MP and the synergetic effects on labile Fe, Mn, S and dissolved organic carbon via in-situ diffusive gradients in thin-films and soil solution sampling techniques. MP with four dosages rapidly and continuously decreased soil labile Cd contents by 14.50 % ∼ 89.16 % in long-term incubation, meanwhile low-dosage MP reduced soil labile Fe and Mn contents, but high-dosage MP increased their contents. With MP dosages increased, the effects of Fe-Mn oxides on soil labile Cd content gradually weakened. MP effectively promoted the reduction of Fe adsorbed by clay minerals and enhanced their ability to adsorb Cd. Short-term incubation showed that MP could decline soil labile Cd by 7.17 % ∼ 44.74 %, especially at the dosage 0.4 %. MP was a reduction catalyst to facilitate Fe reduction, which profited for clay minerals adsorbing Cd. The sorption experiments indicated that 0.30 % MP could adsorb 73.34 % Cd, promote the release of Fe from the soil, and stimulate the ability of clay minerals to adsorb Cd. The results revealed that MP decreased soil labile Cd content within 2 d, and MP made soil Cd activity change out of the influence of soil Fe/Mn redox system. The mechanism will be beneficial for the large-scale application of MP in safe utilization of Cd contaminated soil.
Topics: Soil; Cadmium; Soil Pollutants; Clay; Minerals; Oryza
PubMed: 36244493
DOI: 10.1016/j.scitotenv.2022.159372 -
Journal of Cardiovascular Pharmacology Jun 2023Lipoprotein(a) [Lp(a)] has become an important component of the residual risk of cardiovascular diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK9)... (Meta-Analysis)
Meta-Analysis
Lipoprotein(a) [Lp(a)] has become an important component of the residual risk of cardiovascular diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors display promising effects in controlling Lp(a) levels. However, the effects of different types and dosages of PCSK9 inhibitors on Lp(a) have not been studied in detail. These include 2 monoclonal antibodies, alirocumab and evolocumab, and inclisiran, a small interfering RNA. We searched PubMed, Web of Science, Embase, and Cochrane Library for randomized controlled trials to investigate the efficacy of PCSK9 inhibitors at the Lp(a) level. Although changes in Lp(a) levels were not the primary endpoint in any of these studies, they all described these valuable data. Forty-one randomized controlled trials with 17,601 participants were included, involving 23 unduplicated interventions. Most PCSK9 inhibitors significantly reduced Lp(a) levels compared with placebo. The pairwise comparison demonstrated no significant difference among most PCSK9 inhibitors. However, in the comparison among different dosages of alirocumab, the dosage of 150 mg Q2W showed a significant reduction in Lp(a) levels compared with the dosages of 150, 200, and 300 mg Q4W. In addition, the comparison results demonstrated the significant efficacy of evolocumab 140 mg Q2W compared with alirocumab at a dosage of 150 mg Q4W. The cumulative rank probabilities demonstrated that evolocumab 140 mg Q2W showed the highest efficacy. This study showed that PCSK9 inhibitors reduced Lp(a) levels by up to 25.1%. A biweekly dose of either 140 mg evolocumab or 150 mg alirocumab was the best treatment option. However, the reduction in Lp(a) levels with a single kind of PCSK9 inhibitor alone did not demonstrate sufficient clinical benefit. Therefore, for patients with very high Lp(a) levels who remain at high residual risk in the context of statin administration, it may be acceptable to use a kind of PCSK9 inhibitor, but the clinical benefit needs further investigation.
Topics: Humans; Proprotein Convertase 9; PCSK9 Inhibitors; Lipoprotein(a); Network Meta-Analysis; Subtilisins; Anticholesteremic Agents; Randomized Controlled Trials as Topic
PubMed: 36972559
DOI: 10.1097/FJC.0000000000001419 -
Frontiers in Pharmacology 2022Sirolimus is used to treat pediatric patients with mutation-related immunodeficiency disease. However, the initial dosages of sirolimus remain undecided. The present...
Sirolimus is used to treat pediatric patients with mutation-related immunodeficiency disease. However, the initial dosages of sirolimus remain undecided. The present study aims to explore initial dosages in pediatric patients with mutation-related immunodeficiency disease. Pediatric patients with this disease were analyzed using the population pharmacokinetic (PPK) model and the Monte Carlo simulation. Body weight and concomitant use of posaconazole were included in the final PPK model, where, under the same weight, clearances of sirolimus were 1 : 0.238 between children without and children with posaconazole. Without posaconazole, the initial dosages of sirolimus were 0.07, 0.06, 0.05, and 0.04 mg/kg/day for body weights of 10-14, 14-25, 25-50, and 50-60 kg, respectively. With posaconazole, the initial dosages of sirolimus were 0.02 mg/kg/day for body weights of 10-60 kg. This is the first attempt to build a sirolimus PPK model for recommending initial dosages in children with mutation-related immunodeficiency disease, thereby providing a reference for individualized clinical drug administration.
PubMed: 36188573
DOI: 10.3389/fphar.2022.919487 -
Journal of Dairy Science Jan 2020The objective of this study was to test the effects of essential fatty acids (EFA), particularly α-linolenic acid, and conjugated linoleic acid (CLA) supplementation on...
The objective of this study was to test the effects of essential fatty acids (EFA), particularly α-linolenic acid, and conjugated linoleic acid (CLA) supplementation on fatty acid (FA) composition, performance, and systemic and hepatic antioxidative and inflammatory responses in dairy cows. Four cows (126 ± 4 d in milk) were investigated in a 4 × 4 Latin square and were abomasally infused with 1 of the following for 6 wk: (1) coconut oil (control treatment, CTRL; 38.3 g/d; providing saturated FA), (2) linseed and safflower oil (EFA treatment; 39.1 and 1.6 g/d, respectively; providing mainly α-linolenic acid), (3) Lutalin (BASF, Ludwigshafen, Germany; CLA treatment; cis-9,trans-11 and trans-10,cis-12 CLA, 4.6 g/d each), (4) or EFA+CLA. The initial dosage was doubled every 2 wk, resulting in 3 dosages (dosage 1, 2, and 3). Cows were fed a corn silage-based total mixed ration with a high n-6/n-3 FA ratio. Dry matter intake and milk yield were recorded daily, and milk composition was measured weekly. The FA compositions of milk fat and blood plasma were analyzed at wk 0, 2, 4, and 6. The plasma concentration and hepatic mRNA abundance of parameters linked to the antioxidative and inflammatory response were analyzed at wk 0 and 6 of each treatment period. Infused FA increased in blood plasma and milk of the respective treatment groups in a dose-dependent manner. The n-6/n-3 FA ratio in milk fat was higher in CTRL and CLA than in EFA and EFA+CLA. The sum of FA
dosage-dependent manner. Energy-corrected milk and milk fat decreased in CLA and EFA+CLA in a dosage-dependent manner and were higher in EFA and CTRL than in CLA at dosages 2 and 3. Energy balance tended to be highest in CLA cows. Milk protein content was lower in CLA and EFA+CLA than in CTRL. Milk urea concentration decreased in CLA and EFA+CLA in a dosage-dependent manner and was lower in CLA and EFA+CLA than in EFA and CTRL at dosages 2 and 3. Milk citrate concentration increased in CLA in a dosage-dependent manner and was higher in CLA and EFA+CLA than in EFA and CTRL. Glutathione peroxidase activity in blood plasma was lower in CTRL than in EFA, and plasma concentration of β-carotene increased in EFA and EFA+CLA with dosage. Increased milk citrate pointed at reduced de novo FA synthesis and a better antioxidative status in milk due to CLA treatment. Supplementation with CLA may also affect milk protein synthesis, but EFA and CLA treatment did not influence the inflammatory status in a consistent manner in mid-lactating cows. Topics: Abomasum; Animals; Antioxidants; Cattle; Diet; Dietary Supplements; Drug Administration Routes; Energy Metabolism; Fatty Acids; Female; Inflammation; Injections; Lactation; Linoleic Acids, Conjugated; Milk
PubMed: 31704022
DOI: 10.3168/jds.2019-17135 -
Frontiers in Cellular and Infection... 2023Optimal vancomycin trough concentrations and dosages remain controversial in sepsis children. We aim to investigate vancomycin treatment outcomes with a dosage of 40-60...
BACKGROUND
Optimal vancomycin trough concentrations and dosages remain controversial in sepsis children. We aim to investigate vancomycin treatment outcomes with a dosage of 40-60 mg/kg/d and corresponding trough concentrations in children with Gram-positive bacterial sepsis from a clinical perspective.
METHODS
Children diagnosed with Gram-positive bacterial sepsis and received intravenous vancomycin therapy between January 2017 and June 2020 were enrolled retrospectively. Patients were categorized as success and failure groups according to treatment outcomes. Laboratory, microbiological, and clinical data were collected. The risk factors for treatment failure were analyzed by logistic regression.
RESULTS
In total, 186 children were included, of whom 167 (89.8%) were enrolled in the success group and 19 (10.2%) in the failure group. The initial and mean vancomycin daily doses in failure group were significantly higher than those in success group [56.9 (IQR =42.1-60.0) . 40.5 (IQR =40.0-57.1), P=0.016; 57.0 (IQR =45.8-60.0) . 50.0 (IQR =40.0-57.6) mg/kg/d, P=0.012, respectively] and median vancomycin trough concentrations were similar between two groups [6.9 (4.0-12.1) .7.3 (4.5-10.6) mg/L, P=0.568)]. Moreover, there was no significant differences in treatment success rate between vancomycin trough concentrations ≤15 mg/L and >15 mg/L (91.2% . 75.0%, P=0.064). No vancomycin-related nephrotoxicity adverse effects occurred among all enrolled patients. Multivariate analysis revealed that a PRISM III score ≥10 (OR =15.011; 95% CI: 3.937-57.230; P<0.001) was the only independent clinical factor associated with increased incidence of treatment failure.
CONCLUSIONS
Vancomycin dosages of 40-60 mg/kg/d are effective and have no vancomycin-related nephrotoxicity adverse effects in children with Gram-positive bacterial sepsis. Vancomycin trough concentrations >15 mg/L are not an essential target for these Gram-positive bacterial sepsis patients. PRISM III scores ≥10 may serve as an independent risk factor for vancomycin treatment failure in these patients.
Topics: Humans; Child; Vancomycin; Anti-Bacterial Agents; Retrospective Studies; Treatment Outcome; Sepsis; Gram-Positive Bacterial Infections
PubMed: 37065209
DOI: 10.3389/fcimb.2023.1117717 -
Frontiers in Plant Science 2022Effective strategies to reduce the occurrence of wheat powdery mildew include the use of resistant varieties and application of fungicides. However, most studies rarely...
Effective strategies to reduce the occurrence of wheat powdery mildew include the use of resistant varieties and application of fungicides. However, most studies rarely focus on the quantitative value of fungicide reduction using resistant varieties. To explore how the fungicides performed on different resistant wheat varieties to powdery mildew, field experiments were conducted during wheat growing seasons in 2018/19 and 2019/20 to investigate the control efficacies of enostroburin⋅epoxiconazole 18% SC and triadimefon 20% EC to wheat powdery mildew on a highly resistant wheat variety ("Baofeng104") and a highly susceptible wheat variety ("Jingshuang16"). The analyses of variance on control efficacies showed that the control efficacies of enostroburin⋅epoxiconazole 18% SC to wheat powdery mildew were mostly significantly higher than triadimefon 20% EC under the same conditions (i.e., varieties, dosages). However, both fungicide and variety resistance made variabilities in the mildew disease index and played a significant role in mildew management. Particularly, the variety resistance made the greatest contribution in mildew-reducing, and the disease index could significantly be reduced on the highly resistant variety even in the absence of fungicide treatment. The control efficacies to mildew on the highly susceptible variety mainly depended on the high efficiency of fungicides whereas the highly resistant variety were mainly by virtue of variety resistance through the comparative analyses of linear regression models. Furthermore, the random-coefficient regression models and quantile models quantificationally expounded that the relationships between active ingredient dosage and disease index or control efficacy varied from the effects of variety, fungicide, and year, particular from variety. Thus, a dosage reference table of enostroburin⋅epoxiconazole 18% SC or triadimefon 20% EC for different resistant wheat varieties were provided; it would be helpful for users to formulate an appropriate dosage of fungicide on mildew management in the field and avoid overusing or superfluous application. Further study needs to consider the effects of fungicide reduction on wheat yields, only then the maximum-economic benefits on mildew management can be determined.
PubMed: 35651769
DOI: 10.3389/fpls.2022.864192 -
Bioresource Technology Nov 2022Using low strength wastewater for microalgae cultivation is challenged by slow growth and biomass harvesting issue in suspended systems, and growth-promoting effects of...
Using low strength wastewater for microalgae cultivation is challenged by slow growth and biomass harvesting issue in suspended systems, and growth-promoting effects of phytohormones at currently recommended dosages could neither obtain high enough biomass concentrations nor economic feasibility. This study aims to solve the issues of slow growth, biomass harvest, and phytohormone costs altogether by supplementing low dosage phytohormones in an improved capillary-driven attached cultivation device. The device displayed nutrients-condensing properties, and dosages of indole acetic acid (IAA), 6-benzylaminopurine (6-BA), and salicylic acid (SA) for highest microalgal growth were respectively 10 M, 10 M, and 10 M, being at least one order of magnitude lower than in suspended cultures. SA was most effective in growth-promoting (up to 7.0 g/m biomass density) and nutrients uptake (up to 98.6 % from the bulk environment), while IAA was most effective in antioxidative defenses. These results provided new insights in cost-effective and harvesting-convenient microalgae production.
PubMed: 36244605
DOI: 10.1016/j.biortech.2022.128117 -
Frontiers in Bioengineering and... 2022The dosages and efficacy of 14 ultraviolet (UV) decontamination technologies were measured against a SARS-CoV-2 surrogate virus that was dried onto different materials...
The dosages and efficacy of 14 ultraviolet (UV) decontamination technologies were measured against a SARS-CoV-2 surrogate virus that was dried onto different materials for laboratory and field testing. A live enveloped, ribonucleic acid (RNA) virus surrogate for SARS-CoV-2 was dried on stainless steel 304 (SS304), Navy Top Coat-painted SS304 (NTC), cardboard, polyurethane, polymethyl methacrylate (PMMA), and acrylonitrile butadiene styrene (ABS) materials at > 8.0 log plaque-forming units (PFU) per test coupon. The coupons were then exposed to UV radiation during both laboratory and field testing. Commercial and prototype UV-emitting devices were measured for efficacy: four handheld devices, three room/surface-disinfecting machines, five air disinfection devices, and two larger custom-made machines. UV device dosages ranged from 0.01 to 729 mJ cm. The antiviral efficacy among the different UV devices ranged from no decontamination up to nearly achieving sterilization. Importantly, cardboard required far greater dosage than SS304. Enormous variability in dosage and efficacy was measured among the different UV devices. Porous materials limit the utility of UV decontamination. UV devices have wide variability in dosages, efficacy, hazards, and UV output over time, indicating that each UV device needs independent technical measurement and assessment for product development prior to and during use.
PubMed: 36267449
DOI: 10.3389/fbioe.2022.875817